白细胞介素-38的生物学特性及其在自身免疫性疾病中作用的研究进展

doi:10.20047/j.issn1673-7210.2022.28.11

Abstract
Figure/Table
References (30)
Related Citation (10)

Download: PDF (563 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Interleukin (IL)-38 is a newly discovered anti-inflammatory cytokine and a member of the IL-1 family, which can be widely expressed in a variety of human cells and tissues. Its gene sequence is highly homologous to the genes encoding IL-1 receptor antagonist (IL-1Ra) and IL-36 receptor antagonist (IL-36Ra). Thus, the antagonism of IL-1Ra and IL-36Ra was similar. IL-38 can act on a variety of immune cells, affect the secretion of cytokines, and play an important role in the regulation of immune response. Studies have shown that IL-38 is closely related to the occurrence and development of a variety of autoimmune diseases, which is expected to become a potential target in the future clinical treatment of these diseases. The mechanism of IL-38 is complex, involving the recruitment of specific receptors and the regulation of T helper cell 17 differentiation. A deeper understanding of the role of IL-38 in autoimmune diseases will help further explore its application value in the diagnosis and treatment of diseases. In this review, the biological characteristics of IL-38 and its role in autoimmune diseases are reviewed.

Key words： Interleukin-38 Autoimmune disease T helper cell 17 Interleukin-1 receptor antagonist Interleukin-36 receptor antagonist

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	DAI Wanrong1 ZHANG Yu2 MA Li2

Cite this article:

DAI Wanrong1 ZHANG Yu2 MA Li2. Research progress on biological characteristics of interleukin-38 and its role in autoimmune diseases[J]. 中国医药导报, 2022, 19(28): 54-58.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2022.28.11 OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I28/54

[1] 徐唯傑，马俊，李明才.IL-38的生物学特性及其在肺部疾病中作用的研究进展[J].中国病理生理杂志，2020，36（9）：1715-1720.
[2] van de Veerdonk FL，Netea MG. New Insights in the Immunobiology of IL-1 Family Members [J]. Front Immunol，2013，4：167.
[3] Xie L，Huang Z，Li H，et al. IL-38：A New Player in Inflammatory Autoimmune Disorders [J]. Biomolecules，2019， 9（8）：345.
[4] Dinarello CA. The IL-1 family of cytokines and receptors in rheumatic diseases [J]. Nat Rev Rheumatol，2019，15（10）：612-632.
[5] Hao Z，Liu Y. IL-38 and IL-36 Target Autophagy for Regulating Synoviocyte Proliferation，Migration，and Invasion in Rheumatoid Arthritis [J]. Dis Markers，2021，2021：7933453.
[6] de Graaf DM，Teufel LU，van de Veerdonk FL，et al. IL-38 prevents induction of trained immunity by inhibition of mTOR signaling [J]. J Leukoc Biol，2021，110（5）：907-915.
[7] Li H，Zhu L，Wang R，et al. Therapeutic Effect of IL-38 on Experimental Autoimmune Uveitis：Reprogrammed Immune Cell Landscape and Reduced Th17 Cell Pathogenicity [J]. Invest Ophthalmol Vis Sci，2021，62（15）：31.
[8] Mora J，Schlemmer A，Wittig I，et al. Interleukin-38 is released from apoptotic cells to limit inflammatory macrophage responses [J]. J Mol Cell Biol，2016，8（5）：426-438.
[9] Li J，Liu L，Rui W，et al. New Interleukins in Psoriasis and Psoriatic Arthritis Patients：The Possible Roles of Interleukin-33 to Interleukin-38 in Disease Activities and Bone Erosions [J]. Dermatology，2017，233（1）：37-46.
[10] 韩秋忆，张焱，陈广洁.IL-38及其与类风湿性关节炎关系的研究进展[J].细胞与分子免疫学杂志，2020，36（4）：365-369.
[11] Boutet MA，Nerviani A，Lliso-Ribera G，et al. Interleukin-36 family dysregulation drives joint inflammation and therapy response in psoriatic arthritis [J]. Rheumatology（Oxford），2020，59（4）：828-838.
[12] 肖盼盼，付冰冰，孙雪茜，等.IL-38和IL-17在类风湿关节炎中的表达水平及临床意义[J].湖北民族学院学报（医学版），2019，36（1）：35-37，48.
[13] Boutet MA，Bart G，Penhoat M，et al. Distinct expression of interleukin （IL）-36α，β and γ，their antagonist IL-36Ra and IL-38 in psoriasis，rheumatoid arthritis and Crohn’s disease [J]. Clin Exp Immunol，2016，184（2）：159-173.
[14] 裴冰，陈克研，吴腾飞，等.SIRT1/HIF-1α信号通路介导IL-38改善胶原诱导性关节炎大鼠Th17/Treg失衡[J].解剖科学进展，2021，27（2）：164-168.
[15] 张继云，王梅，赵旌，等.IL-38对类风湿关节炎患者辅助性T细胞17转录因子的影响[J].广东医学，2021，42（2）：226-228，233.
[16] Kim HJ，Kim SH，Park J，et al. Up-regulation of receptor antagonist interleukin-1 family members in psoriasis and their regulation by pro-inflammatory cytokines [J]. J Dermatol Sci，2016，82（3）：204-206.
[17] Madonna S，Girolomoni G，Dinarello CA，et al. The Significance of IL-36 Hyperactivation and IL-36R Targeting in Psoriasis [J]. Int J Mol Sci，2019，20（13）：3318.
[18] Han Y，Mora J，Huard A，et al. IL-38 Ameliorates Skin Inflammation and Limits IL-17 Production from γδ T Cells [J]. Cell Rep，2019，27（3）：835-846.e5.
[19] Mercurio L，Morelli M，Scarponi C，et al. IL-38 has an anti-inflammatory action in psoriasis and its expression correlates with disease severity and therapeutic response to anti-IL-17A treatment [J]. Cell Death Dis，2018，9（11）：1104.
[20] Boutet MA，Nerviani A，Pitzalis C. IL-36，IL-37，and IL-38 Cytokines in Skin and Joint Inflammation：A Comprehensive Review of Their Therapeutic Potential [J]. Int J Mol Sci，2019，20（6）：1257.
[21] Xu WD，Su LC，Liu XY，et al. IL-38：A novel cytokine in systemic lupus erythematosus pathogenesis [J]. J Cell Mol Med，2020，24（21）：12379-12389.
[22] Chu M，Tam LS，Zhu J，et al. In vivo anti-inflammatory activities of novel cytokine IL-38 in Murphy Roths Large（MRL）/lpr mice [J]. Immunobiology，2017，222（3）：483-493.
[23] Ohno M，Imai T，Chatani M，et al. The anti-inflammatory and protective role of interleukin-38 in inflammatory bowel disease [J]. J Clin Biochem Nutr，2022，70（1）：64-71.
[24] Xie C，Yan W，Quan R，et al. Interleukin-38 is elevated in inflammatory bowel diseases and suppresses intestinal inflammation [J]. Cytokine，2020，127：154963.
[25] Pan Y，Wang M，Chen X，et al. Elevated IL-38 inhibits IL-23R expression and IL-17A production in thyroid-associated ophthalmopathy [J]. Int Immunopharmacol，2021，91：107300.
[26] Shi L，Ye H，Huang J，et al. IL-38 Exerts Anti-Inflammatory and Antifibrotic Effects in Thyroid-Associated Ophthalmopathy [J]. J Clin Endocrinol Metab，2021，106（8）：e3125-e3142.
[27] Zarrabi M，Nazarinia M，Rahimi Jaberi A，et al. Elevated IL-38 Serum Levels in Newly Diagnosed Multiple Sclerosis and Systemic Sclerosis Patients [J]. Med Princ Pract，2021，30（2）：146-153.
[28] Huard A，Do HN，Frank AC，et al. IL-38 Ablation Reduces Local Inflammation and Disease Severity in Experimental Autoimmune Encephalomyelitis [J]. J Immunol，2021，206（5）：1058-1066.
[29] Zarrabi M，Gholijani N，Shenavandeh S，et al. IL-38 serum levels in patients with Behcet’s disease and the relationship with clinical features [J]. Eur Cytokine Netw，2019，30（3）：82-87.
[30] Luo D，Chen Y，Zhou N，et al. Blockade of Th17 response by IL-38 in primary Sj?觟gren’s syndrome [J]. Mol Immunol，2020，127：107-111.